AstraZeneca Pharmaceuticals LP
2746 articles about AstraZeneca Pharmaceuticals LP
-
CinCor Pharma to be Acquired by AstraZeneca
1/9/2023
CinCor Pharma, Inc. announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.
-
Press Release: FDA accepts nirsevimab application as first protective option against RSV disease for all infants
1/5/2023
The U.S. Food and Drug Administration Center for Drug Evaluation and Research has accepted the Biologics License Application for nirsevimab for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants entering or during their first RSV season and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
-
Lightnix decided to participate as a partner company in i2.JP led by AstraZeneca
12/26/2022
Lightnix Inc. has decided to participate as a partner company in "Innovation Infusion Japan”, an initiative sponsored by AstraZeneca K.K. i2.JP is a new initiative that promotes open innovations in the healthcare field.
-
Setting the Stage for ASH 2022
12/9/2022
At ASH 2022, established hematology leaders like AstraZeneca, Janssen and Merck will showcase new data, and new players like Vega Therapeutics will launch new programs. -
AstraZeneca posted two mid-stage wins at the 2022 San Antonio Breast Cancer Symposium on Thursday, touting the efficacy of capivasertib and camizestrant against breast cancer.
-
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
12/8/2022
Detailed results from the CAPItello-291 Phase III trial showed AstraZeneca’s capivasertib in combination with FASLODEX® demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo plus FASLODEX in patients with hormone receptor -positive, human epidermal growth factor receptor 2 -low or negative, locally advanced or metastatic breast cancer, following recurrence or progression on, or after, endocrine therapy.
-
Datopotamab Deruxtecan Showed Encouraging and Durable Efficacy in Patients with Heavily Pretreated HR Positive, HER2 Low or Negative Metastatic Breast Cancer
12/8/2022
Initial results from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan showed encouraging and durable efficacy in patients with heavily pretreated hormone receptor positive, HER2 low or HER2 negative unresectable or metastatic breast cancer.
-
Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca’s Manufacturing Site in West Chester, Ohio
11/29/2022
National Resilience, Inc. (Resilience) and AstraZeneca PLC announced today that the companies will establish a long-term biomanufacturing relationship in support of AstraZeneca’s portfolio.
-
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company.
-
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme
11/28/2022
C4X Discovery Holdings plc, a pioneering Drug Discovery company, has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million1, for its NRF2 Activator programme.
-
C4X entered into a licensing deal with AstraZeneca to develop an oral treatment for COPD and other inflammatory and respiratory illnesses that could reach $402 million.
-
Large pharmaceutical companies are making plans to comply with sustainability and carbon net zero targets. Hear from AstraZeneca and Merck KGaA's MilliporeSigma about their strategies.
-
AstraZeneca dosed the first patient in a Phase II portion of an ongoing trial assessing a PD-1/TIGIT bispecific antibody, triggering a $7.5 million milestone payment to partner, Compugen.
-
ImpediMed Extends Contract for AstraZeneca for Use of the SOZO Digital Health Platform in Clinical Trial of Patients with Chronic Kidney Disease
11/16/2022
ImpediMed Limited (ASX: IPD) today announced the details of the third contract extension related to the use of its SOZO® Digital Health Platform in a clinical trial being conducted for AstraZeneca.
-
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
11/14/2022
AstraZeneca and Merck (NYSE: MRK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of LYNPARZA in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.
-
The FDA approved AstraZeneca’s Imfinzi in combination with Imjudo and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer.
-
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
11/11/2022
AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).
-
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
11/10/2022
TIME named AstraZeneca’s EVUSHELD on their 2022 list of Best Inventions.
-
AstraZeneca will give up on seeking approval for its COVID-19 vaccine in the United States. It is also abandoning three early-stage programs.
-
The FDA deemed AstraZeneca’s PT027 to have a favorable risk-benefit profile for treating asthma in patients aged 18 or older but was less keen on supporting the drug in younger populations.